Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingGlobeNewsWire • 12/10/23
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)GlobeNewsWire • 11/14/23
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingGlobeNewsWire • 11/03/23
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/02/23
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitGlobeNewsWire • 11/01/23
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioGlobeNewsWire • 10/26/23
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual MeetingGlobeNewsWire • 09/13/23
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023GlobeNewsWire • 06/27/23
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual MeetingGlobeNewsWire • 05/25/23
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare ConferenceGlobeNewsWire • 05/16/23
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio StrategyGlobeNewsWire • 05/11/23
Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACRGlobeNewsWire • 04/14/23
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General MeetingGlobeNewsWire • 04/04/23
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022GlobeNewsWire • 03/09/23
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care ConferenceGlobeNewsWire • 03/02/23
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy PlatformGlobeNewsWire • 02/28/23
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 01/16/23
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor ConferencesGlobeNewsWire • 12/30/22
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AMLGlobeNewsWire • 12/13/22